We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Classic Mediterranean Kaposi’s Sarcoma Regression With Sirolimus Treatment

Emmanuella Guenova, MD; Gisela Metzler, MD; Wolfram Hoetzenecker, MD, PhD; Mark Berneburg, MD; Martin Rocken, MD
Arch Dermatol. 2008;144(5):692-693. doi:10.1001/archderm.144.5.692.
Text Size: A A A
Published online


Replacement of mycophenolate mofetil, cyclosporine, or tacrolimus by sirolimus results in regression of Kaposi's sarcoma (KS) in organ transplant recipients.13 In these patients, clearance from KS might result either from reduced immunosuppression or from the direct antiangiogenic effects of sirolimus.

Boeckle  EBoesmueller  CWiesmayr  S  et al.  Kaposi sarcoma in solid organ transplant recipients: a single center report. Transplant Proc 2005;37 (4) 1905- 1909
PubMed Link to Article[[XSLOpenURL/10.1016/j.transproceed.2005.03.144]]
Stallone  GSchena  AInfante  B  et al.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352 (13) 1317- 1323
PubMed Link to Article[[XSLOpenURL/10.1056/NEJMoa042831]]
Weenink  JJGroeneveld  JOde Fijter  CW Sirolimus monotherapy for Kaposi's sarcoma in an HIV-negative patient. Lancet Oncol 2006;7 (10) 875- 876
PubMed Link to Article[[XSLOpenURL/10.1016/S1470-2045(06)70907-X]]
Sodhi  AChaisuparat  RHu  J  et al.  The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006;10 (2) 133- 143
PubMed Link to Article[[XSLOpenURL/10.1016/j.ccr.2006.05.026]]
Guba  Mvon Breitenbuch  PSteinbauer  M  et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8 (2) 128- 135
PubMed Link to Article[[XSLOpenURL/10.1038/nm0202-128]]
Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Regression of classic Kaposi's sarcoma in a 62-year-old immunocompetent man without human immunodeficiency virus receiving sirolimus monotherapy (hematoxylin-eosin, original magnification ×100 for both histologic views). A, Pretreatment clinical and histologic views. B, Clinical and histologic views after 2 months of sirolimus therapy at a blood concentration of 6 ng/mL.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

14 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Cancer and mTOR inhibitors in Transplant Recipients. Transplantation Published online Aug 10, 2016;